Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment

References

• Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol. 2015;76(6):1113–1132. doi:10.1007/s00280-015-2861-126391154
   PubMed Web of Science ®Google Scholar
• Scott LJ. Lenvatinib: first global approval. Drugs. 2015;75(5):553–560. doi:10.1007/s40265-015-0383-025795101
   PubMed Web of Science ®Google Scholar
• Lenvima® (Lenvatinib). Summary of product characteristics. Hatfield (UK): Eisai Europe Limited, European Knowledge Centre, Mosquito Way; 2015.
   Google Scholar
• Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol. 2016;81(6):1124–1133. doi:10.1111/bcp.1290726879594
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Rosing H, Thijssen B, et al. Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;887-888:25–34. doi:10.1016/j.jchromb.2012.01.004
   PubMed Web of Science ®Google Scholar
• Koyama N, Saito K, Nishioka Y, et al. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer. 2014;14:530. doi:10.1186/1471-2407-14-53025047123
   PubMed Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747. doi:10.1155/2014/63874725295214
   PubMedGoogle Scholar
• Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664–671. doi:10.1002/ijc.2313117943726
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:6–18. doi:10.1186/2045-824X-6-624628920
   PubMedGoogle Scholar
• Matsui J, Funahashi Y, Uenaka T, et al. Multi-Kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459–5465. doi:10.1158/1078-0432.CCR-07-527018765537
   PubMed Web of Science ®Google Scholar
• Ikuta K, Yano S, Trung VT, et al. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res. 2009;15(23):7229–7237. doi:10.1158/1078-0432.CCR-09-198019934291
   PubMed Web of Science ®Google Scholar
• Ogino H, Hanibuchi M, Kakiuchi S, et al. E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther. 2011;10(7):1218–1228. doi:10.1158/1535-7163.MCT-10-070721551260
   PubMed Web of Science ®Google Scholar
• Russo A, Franchina T, Ricciardi GRR, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit Rev Oncol Hematol. 2017;117:38–47. doi:10.1016/j.critrevonc.2017.07.00328807234
   PubMed Web of Science ®Google Scholar
• Bruheim S, Kristian A, Uenaka T, et al. Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int J Cancer. 2011;129:742–750. doi:10.1002/ijc.2592221225632
   PubMed Web of Science ®Google Scholar
• Glen H, Mason S, Patel H, et al. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer. 2011;11:309. doi:10.1186/1471-2407-11-30921781317
   PubMed Web of Science ®Google Scholar
• Wiegering A, Korb D, Thalheimer A, et al. E7080 (Lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. Neoplasia. 2014;16(11):972–981. doi:10.1016/j.neo.2014.09.00825425971
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Matsushima T, Kawano S, et al. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci. 2014;105(6):723–730. doi:10.1111/cas.1240924689876
   PubMed Web of Science ®Google Scholar
• Nakazawa Y, Kawano S, Matsui J, et al. Multitargeting strategy using Lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model. Cancer Sci. 2015;106(2):201–207. doi:10.1111/cas.1258125458359
   PubMed Web of Science ®Google Scholar
• Li J, Zou CL, Zhang ZM, et al. A multitargeted tyrosine kinase inhibitor Lenvatinib for the treatment of mice with advanced glioblastoma. Mol Med Rep. 2017;16(5):7105–7111. doi:10.3892/mmr.2017.745628901423
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783–2795. doi:10.1016/S0140-6736(16)30172-627240885
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103. doi:10.1016/j.canlet.2013.07.00723856031
   PubMed Web of Science ®Google Scholar
• Jing C, Gao Z, Wang R, et al. Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017;7(4):903–912.28469962
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Bocci G, Di Desidero T, et al. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018;39(5):2225–2234. doi:10.3892/or.2018.630629517103
   PubMed Web of Science ®Google Scholar
• Incio J, Tam J, Rahbari NN, et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res. 2016;22(12):2993–3004. doi:10.1158/1078-0432.CCR-15-183926861455
   PubMed Web of Science ®Google Scholar
• Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19(1):31–44. doi:10.1016/j.ccr.2010.11.00921215706
   PubMed Web of Science ®Google Scholar
• Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11):1194–1201. doi:10.1038/nm1101-119411689883
   PubMed Web of Science ®Google Scholar
• Chen XW, Yu TJ, Zhang J, et al. CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis. Oncogene. 2017;36(35):5045–5057. doi:10.1038/onc.2017.11828481877
   PubMed Web of Science ®Google Scholar
• Naoum GE, Morkos M, Kim B, Arafat W. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer. 2018;17(1):51. doi:10.1186/s12943-018-0786-029455653
   PubMedGoogle Scholar
• Mehnert JMVA, Brose M, Aggarwal R, et al. Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. In: American Society of Clinical oncology (ASCO) annual meeting: Chicago. J Clin Oncol. 2016;34(suppl; abstr 6091). doi:10.1200/JCO.2016.34.15_suppl.6091
   Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148. doi:10.1084/jem.2014055925601652
   PubMed Web of Science ®Google Scholar
• Cai C, Tang J, Shen B, et al. Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy (T cells sensitized to neopalastic cells) for treatment of renal cell carcinoma. Exp Ther Med. 2017;14(4):3221–3228. doi:10.3892/etm.2017.485828912872
   PubMed Web of Science ®Google Scholar
• Taylor M, Dutcus CE, Schmidt E, et al. 776PD-A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors. Ann Oncol. 2016;27(6):266–295. doi:10.1093/annonc/mdw373.04
   Google Scholar
• Yamada K, Yamamoto N, Yamada Y, et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 2011;15(8):2528–2537. doi:10.1158/1078-0432.CCR-10-2638
   Google Scholar
• Garmy-Susini B, Varner JA. Circulating endothelial progenitor cells. Br J Cancer. 2005;93(8):855–858. doi:10.1038/sj.bjc.660280816189517
   PubMed Web of Science ®Google Scholar
• Mancuso P, Bertolini F. Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res. 2010;79(3):224–228. doi:10.1016/j.mvr.2010.02.00720176038
   PubMed Web of Science ®Google Scholar
• Boss DS, Glen H, Beijnen JH, et al. Phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106(10):1598–1604. doi:10.1038/bjc.2012.15422516948
   PubMed Web of Science ®Google Scholar
• Nishio M, Horai T, Horiike A, et al. Phase 1 study of Lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer. 2013;109(3):538–544. doi:10.1038/bjc.2013.37423860537
   PubMed Web of Science ®Google Scholar
• Molina AM, Hutson TE, Larkin J, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) cancer. Chemother Pharmacol. 2014;73(1):181–189. doi:10.1007/s00280-013-2339-y
   PubMed Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Wheler JJ, et al. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res. 2015;21(21):4801–4810. doi:10.1158/1078-0432.CCR-14-306326169970
   PubMed Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Falchook GS, et al. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 2015;6(40):43127–43134. doi:10.18632/oncotarget.575626503473
   PubMedGoogle Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New Engl J Med. 2015;372:2006–2017. doi:10.1056/NEJMoa141442825891304
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482. doi:10.1016/S1470-2045(15)00290-926482279
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2016;22(1):44–53. doi:10.1158/1078-0432.CCR-15-112726311725
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749–2756. doi:10.1002/cncr.2939525913680
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi:10.1056/NEJMoa140647025671254
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52(4):512–519. doi:10.1007/s00535-016-1263-427704266
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-129433850
   PubMed Web of Science ®Google Scholar
• Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018;12(4):361–373. doi:10.1007/s11684-018-0656-630043221
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim SM, Kim BW, et al. Anti-cancer effects of HNHA and lenvatinib by the suppression of EMT-mediated drug resistance in cancer stem cells. Neoplasia. 2018;20(2):197–206. doi:10.1016/j.neo.2017.12.00329331886
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi:10.1038/nrm375824556840
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies – a review. J Adv Res. 2017;8(6):591–605. doi:10.1016/j.jare.2017.06.00628808589
   PubMed Web of Science ®Google Scholar
• Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle. 2009;8(1):18–22. doi:10.4161/cc.8.1.732419106609
   PubMed Web of Science ®Google Scholar
• Sennino B, Md DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer. 2012;12(10):699–709. doi:10.1038/nrc336623001349
   PubMed Web of Science ®Google Scholar
• Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70:10090–10100. doi:10.1158/0008-5472.CAN-10-048920952508
   PubMed Web of Science ®Google Scholar
• Luo M, Fu LW. Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. Am J Cancer Res. 2014;4(6):608–628.25520855
   PubMed Web of Science ®Google Scholar
• Saji M, Ringel MD. The PI3K-AKT-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321(1):20–28. doi:10.1016/j.mce.2009.10.01619897009
   PubMed Web of Science ®Google Scholar
• Ghidini M, Petrelli F, Ghidini A, et al. Clinical development of mTor inhibitors for renal cancer. Expert Opin Investig Drugs. 2017;26(11):1229–1237. doi:10.1080/13543784.2017.1384813
   PubMed Web of Science ®Google Scholar
• Scoazec JY. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology. 2013;97(1):45–56. doi:10.1159/00033837122538258
   PubMed Web of Science ®Google Scholar
• Capozzi M, Von Arx C, De Divitiis C, et al. Antiangiogenic therapy in pancreatic neuroendocrine tumors. Anticancer Res. 2016;36(10):5025–5030. doi:10.21873/anticanres.1107127798861
   PubMed Web of Science ®Google Scholar